Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 183

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 1B
Chunk 183
---
 for obligations related to the ATOM Lease. See Note 7 – “Leases” in the Notes to Consolidated Financial Statements, included in Item 8. Financial Statements and Supplementary Data of this report for further information on our lease obligations. 

We enter into contracts in the normal course of business with clinical research organizations for clinical studies, with CMOs for clinical and commercial materials, and with other vendors for preclinical studies and supplies and other services and products for operating purposes. These contracts generally provide for termination for convenience following a notice period. We have non-cancellable minimum commitments for products and services, subject to agreements with a term of greater than one year with clinical research organizations and CMOs. See Note 9 – “Commitments and Contingencies” in the Notes to Consolidated Financial Statements, included in Item 8. Financial Statements and Supplementary Data of this report for further information on our contractual obligations and commitments. 

Cash Flows 

Comparison of the Years Ended December 31, 2024 and 2023

The following table details the primary sources and uses of cash for each of the periods set forth below: 

    Year Ended December 31,

    2024

    2023

    (in thousands)

    Net cash (used in) provided by:

    Operating activities
     
    $
    (68,717
    )
     
    $
    (192,977
    )

    Investing activities

    8,624

    123,866

    Financing activities

    59,282

    2,010

    Net decrease in cash, cash equivalents and restricted cash
     
    $
    (811
    )
     
    $
    (67,101
    )

93

Operating activities 

Net cash used in operating activities was $68.7 million in 2024 as compared to $193.0 million in 2023. The decrease of $124.3 million was primarily due to lower cash operating expenses in 2024 as compared to 2023, primarily due to lower compensation-related costs resulting from lower headcount driven by November 2023 and January 2024 reductions in force, as well as the $40.0 million received from Pierre Fabre in 2023 for development milestones met in December 2022, with no similar cash flows received in 2024. 

Investing activities 

Net cash provided by investing activities in 2024 consisted of $28.5 million received from maturities and